Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing results from a Phase III trial that were announced ...
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...
Dissolvable film BNT23001 led to about 40% higher cladribine exposure than tablets in a preclinical pig study, BioNxt ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental and closely watched drug for multiple ...
Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...
BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...
BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results